• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

转移性黑色素瘤的全身治疗

Systemic Therapy in Metastatic Melanoma.

作者信息

Goyal Gaurav, Silberstein Peter T

机构信息

is a house officer in the Department of Internal Medicine and is a professor and chief of Hematology/Oncology, both at CHI Health Creighton University Medical Center in Omaha, Nebraska. Dr. Silberstein is also the chief of oncology at VA Nebraska-Western Iowa Healthcare System in Omaha.

出版信息

Fed Pract. 2015 May;32(Suppl 4):57S-65S.

PMID:30766124
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6375453/
Abstract

New targeted treatments and therapies for metastatic melanoma are improving patient prognosis and survival.

摘要

转移性黑色素瘤的新型靶向治疗方法正在改善患者的预后和生存率。

相似文献

1
Systemic Therapy in Metastatic Melanoma.转移性黑色素瘤的全身治疗
Fed Pract. 2015 May;32(Suppl 4):57S-65S.
2
A Population-based Study of Survival Impact of New Targeted and Immune-based Therapies for Metastatic or Unresectable Melanoma.基于人群的研究：新的靶向和免疫治疗对转移性或不可切除黑色素瘤的生存影响。
Clin Oncol (R Coll Radiol). 2018 Oct;30(10):609-617. doi: 10.1016/j.clon.2018.05.005. Epub 2018 Jun 28.
3
Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologists.转移性黑色素瘤患者治疗中的靶向治疗与免疫检查点抑制剂：病理学家指南及更新
Pathology. 2016 Feb;48(2):194-202. doi: 10.1016/j.pathol.2015.12.010. Epub 2016 Jan 20.
4
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.黑色素瘤研究的未来展望：“黑色素瘤桥梁”会议报告：那不勒斯，2014年12月3日至6日
J Transl Med. 2015 Nov 30;13:374. doi: 10.1186/s12967-015-0736-1.
5
Systemic therapy of metastatic melanoma: on the road to cure.转移性黑色素瘤的系统治疗：走向治愈之路。
Oncology (Williston Park). 2015 Feb;29(2):126-35.
6
The potential complementary role of targeted alpha therapy in the management of metastatic melanoma.靶向α治疗在转移性黑色素瘤管理中的潜在补充作用。
Melanoma Manag. 2015 Nov;2(4):353-366. doi: 10.2217/mmt.15.26. Epub 2015 Nov 24.
7
Treatment of metastatic melanoma: a multidisciplinary approach.
G Ital Dermatol Venereol. 2017 Jun;152(3):241-261. doi: 10.23736/S0392-0488.17.05633-4. Epub 2017 Mar 14.
8
Surgical management of metastatic melanoma in the era of targeted systemic therapies.靶向全身治疗时代转移性黑色素瘤的外科治疗
Melanoma Res. 2015 Feb;25(1):1-8. doi: 10.1097/CMR.0000000000000128.
9
The use of systemic therapies for the treatment of brain metastases in metastatic melanoma: opportunities and unanswered questions.系统治疗在转移性黑色素瘤脑转移中的应用：机遇与未解问题。
Cancer Treat Rev. 2013 Dec;39(8):833-8. doi: 10.1016/j.ctrv.2013.06.004. Epub 2013 Jul 9.
10
Current and emerging systemic therapies for cutaneous metastatic melanoma.皮肤转移性黑色素瘤的现有和新兴系统治疗方法。
Expert Opin Pharmacother. 2019 Jun;20(9):1135-1152. doi: 10.1080/14656566.2019.1601700. Epub 2019 Apr 26.

引用本文的文献

1
Neoantigen mRNA vaccines and AA receptor antagonism: A strategy to enhance T cell immunity.新抗原mRNA疫苗与AA受体拮抗作用：增强T细胞免疫的一种策略。
Hum Vaccin Immunother. 2025 Dec;21(1):2458936. doi: 10.1080/21645515.2025.2458936. Epub 2025 Jan 30.
2
Negative Influence of Aging on Differentiation and Proliferation of CD8 T-Cells in Dogs.衰老对犬CD8 T细胞分化和增殖的负面影响
Vet Sci. 2023 Aug 25;10(9):541. doi: 10.3390/vetsci10090541.
3
Antitumor Effect of Metformin in Combination with Binimetinib on Melanoma Cells.二甲双胍联合比美替尼对黑色素瘤细胞的抗肿瘤作用
Dev Reprod. 2021 Jun;25(2):93-104. doi: 10.12717/DR.2021.25.2.93. Epub 2021 Jun 30.
4
Hereditary cancer syndromes: utilizing DNA repair deficiency as therapeutic target.遗传性癌症综合征：将DNA修复缺陷作为治疗靶点
Fam Cancer. 2016 Jul;15(3):359-66. doi: 10.1007/s10689-016-9883-7.

本文引用的文献

1
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.伊匹单抗治疗不可切除或转移性黑色素瘤的II期和III期试验长期生存数据的汇总分析
J Clin Oncol. 2015 Jun 10;33(17):1889-94. doi: 10.1200/JCO.2014.56.2736. Epub 2015 Feb 9.
2
Nivolumab in previously untreated melanoma without BRAF mutation.纳武利尤单抗治疗未经 BRAF 突变检测的初治黑色素瘤。
N Engl J Med. 2015 Jan 22;372(4):320-30. doi: 10.1056/NEJMoa1412082. Epub 2014 Nov 16.
3
Improved overall survival in melanoma with combined dabrafenib and trametinib.达拉非尼和曲美替尼联合治疗可改善黑色素瘤患者的总生存期。
N Engl J Med. 2015 Jan 1;372(1):30-9. doi: 10.1056/NEJMoa1412690. Epub 2014 Nov 16.
4
Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial.伊匹单抗联合沙格司亭与单用伊匹单抗治疗转移性黑色素瘤：一项随机临床试验。
JAMA. 2014 Nov 5;312(17):1744-53. doi: 10.1001/jama.2014.13943.
5
Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.联合维莫非尼和考比替尼治疗 BRAF 突变型黑色素瘤。
N Engl J Med. 2014 Nov 13;371(20):1867-76. doi: 10.1056/NEJMoa1408868. Epub 2014 Sep 29.
6
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.BRAF 和 MEK 联合抑制与单独 BRAF 抑制治疗黑色素瘤。
N Engl J Med. 2014 Nov 13;371(20):1877-88. doi: 10.1056/NEJMoa1406037. Epub 2014 Sep 29.
7
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.派姆单抗治疗伊匹单抗难治性晚期黑色素瘤的抗程序性死亡受体 1 治疗：一项 I 期试验的随机剂量比较队列。
Lancet. 2014 Sep 20;384(9948):1109-17. doi: 10.1016/S0140-6736(14)60958-2. Epub 2014 Jul 15.
8
The nature and management of metastatic melanoma after progression on BRAF inhibitors: effects of extended BRAF inhibition.BRAF 抑制剂治疗进展后的转移性黑色素瘤的性质和管理：延长 BRAF 抑制的效果。
Cancer. 2014 Oct 15;120(20):3142-53. doi: 10.1002/cncr.28851. Epub 2014 Jul 1.
9
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.纳武利尤单抗治疗晚期黑色素瘤患者的生存、持久肿瘤缓解和长期安全性。
J Clin Oncol. 2014 Apr 1;32(10):1020-30. doi: 10.1200/JCO.2013.53.0105. Epub 2014 Mar 3.
10
Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.维莫非尼治疗 BRAF(V600) 突变转移性黑色素瘤患者：一项开放性、多中心、安全性研究。
Lancet Oncol. 2014 Apr;15(4):436-44. doi: 10.1016/S1470-2045(14)70051-8. Epub 2014 Feb 27.